Dudediligence.

Sarepta Therapeutics, Inc

SRPTNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$429.8MSep ’24$658.4MDec ’24$611.5MMar ’25$513.1MJun ’25$370.0MSep ’25$442.9MDec ’25$730.8MMar ’26$328.7MJun ’26
Net income, by quarter
$33.6MSep ’24$159.0MDec ’24−$447.5MMar ’25$196.9MJun ’25−$50.6MSep ’25−$412.2MDec ’25$331.0MMar ’26−$4.9MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$612.4M$843.8M$1.14B$1.79B$1.86B
Gross profitnone on filenone on filenone on filenone on file$1.84B
Operating income−$459.7M−$536.2M−$267.8M$218.1M−$699.8M
Net income−$418.8M−$703.5M−$536.0M$235.2M−$713.4M
Operating cash flow−$443.2M−$325.3M−$501.0M−$205.8M−$205.5M
Free cash flow−$481.7M−$356.2M−$577.1M−$342.7M−$307.5M
Cash$2.12B$966.8M$428.4M$1.10B$801.3M
Debt$563.7M$1.54B$1.34B$1.14B$829.0M
Shares outstanding87.1M88.0M93.7M96.9M105.0M